Zobrazeno 1 - 10
of 238
pro vyhledávání: '"James F Donohue"'
Autor:
James F Donohue, Paul W Jones
Publikováno v:
International Journal of COPD, Vol 2011, Iss default, Pp 35-45 (2011)
James F Donohue1, Paul W Jones21Division of Pulmonary Disease and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2St. George's, University of London, London, UKAbstract: Chronic obstruct
Externí odkaz:
https://doaj.org/article/88de7009f1f346039c0cca61b06a6274
Autor:
Nicholas J Gross, James F Donohue
Publikováno v:
International Journal of COPD, Vol 2010, Iss default, Pp 223-232 (2010)
Nicholas J Gross1, James F Donohue21Hines VA Hospital, Stritch Loyola School of Medicine, Hines, IL, USA; 2University of North Carolina School of Medicine, Chapel Hill, NC, USAAbstract: A nebulized formulation of formoterol, Perforomist®, 20 μg/2 m
Externí odkaz:
https://doaj.org/article/0cfc2e81297d4636a0dcb0db2b1a9dfd
Autor:
James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, Glenn Crater
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background Revefenacin is a long-acting muscarinic antagonist that was recently approved for the nebulized treatment of chronic obstructive pulmonary disease (COPD). Although shorter duration studies have documented the efficacy of revefenac
Externí odkaz:
https://doaj.org/article/198bfe3495a340e7a38a0033b3384475
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-11 (2019)
Abstract There is increasing focus on understanding the nature of chronic obstructive pulmonary disease (COPD) during the earlier stages. Mild COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 1 or the now-withdrawn GOLD stage
Externí odkaz:
https://doaj.org/article/872508be2b0a43eba03b4bc667348614
Autor:
Anthony D’Urzo, Kenneth R. Chapman, James F. Donohue, Peter Kardos, M. Reza Maleki-Yazdi, David Price
Publikováno v:
Pulmonary Therapy, Vol 5, Iss 1, Pp 23-41 (2019)
Abstract Inhaled fixed-dose combinations (FDCs) of a long-acting β-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD trea
Externí odkaz:
https://doaj.org/article/3443b8b843c74a90940133ed346ce692
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Background: Combinations of a long-acting muscarinic receptor antagonist (LAMA), long-acting β-agonist (LABA), and inhaled corticosteroid (ICS) are used for patients with persistent chronic obstructive pulmonary disease (COPD) exacerbations on bronc
Externí odkaz:
https://doaj.org/article/1c2a47d957cd4efa80a10a3aa452b662
Publikováno v:
Respiratory Research, Vol 18, Iss 1, Pp 1-9 (2017)
Abstract Background Long-acting muscarinic antagonists (LAMAs) are recommended for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate/eFlow® is an investigational drug–device combination of the LAMA glycopyrrolate admini
Externí odkaz:
https://doaj.org/article/bb250a163c8142df9b65637c73beb68a
Autor:
Roy A. Pleasants, Khosrow Heidari, Jill Ohar, James F. Donohue, Njira L. Lugogo, Sarojini M. Kanotra, Monica Kraft, David M. Mannino, Charlie B. Strange
Publikováno v:
Pulmonary Therapy. 8:255-268
Data collected through ongoing, state-based, cross-sectional health surveys could be used to better understand the contribution of respiratory symptoms to impaired health among the US adult population.We used the 2015 Behavioral Risk Factor Surveilla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84251e4d02f5e9f0942229218a6a1ea5
https://doi.org/10.1007/s41030-022-00194-9
https://doi.org/10.1007/s41030-022-00194-9
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 13 (2019)
Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 µg is a twice-daily long-acting muscarinic receptor antagonist and long-acting β 2 agonist (LAMA/LABA) dual-bronchodilator maintenance therapy used to relieve symptoms and reduce future risk of
Externí odkaz:
https://doaj.org/article/c437b392709e4e578bee31fe65cdefb1
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9ae9256a8dba7e2e6407097d97099aa
https://doi.org/10.1164/rccm.202012-4322le
https://doi.org/10.1164/rccm.202012-4322le